Growth Track
G4A provides digital health tech startups with a gateway to accessing digital health partnerships with Bayer Pharma. We develop relationships with each startup, and tailor our partnership to their needs–providing resources, expertise, and connections to amplify and accelerate their business without giving up equity as a requirement.
As technology improves and becomes more accessible to more people, digital health will be the new foundation of healthcare across the entire system. G4A is participating in and enabling that transformation.
Why should you be interested in the Growth Track?

We provide you
with the financing
you need to take off
Our Growth Track startups gain a EUR 25,000 to EUR 100,000 convertible loan.
Mentorship by
industry experts
Growth Track Startups receive personalised mentorship, by Bayer executives and external industry experts. Individualised coaching ensures Startups enter the healthcare market successfully.

Our success stories
24+
Growth Track companies
$71.6M
Total funding raised
$122M
Total Alumni Value
Our success stories
24+
Growth Track companies
$71.6M
Total funding raised
$122M
Total Alumni Value
Current Challenges
Lifestyle Behavior Change
Cardiometabolic and Renal Diseases
Lifestyle Behavior Change
Cardiovascular diseases cause 31% of all global deaths1. Behavioral risk factors including unhealthy diet, physical inactivity, tobacco use, and harmful use of alcohol can contribute to the onset and progression of cardiovascular disease.
- We are looking for companies that are developing behavior change solutions which reduce the progression of cardio-metabolic conditions (such as hypertension, chronic artery disease, etc.)
- We are looking for companies that are developing behavior change solutions addressing specifically the risk factors of cardio-metabolic conditions. For example, solutions which address and improve sleep health, improve mental health or support smoking cessation.
Open to both Growth and Advanced Tracks
Geographical Region Scalability: US, Germany, France, UK, China
Patient Monitoring and Digital Biomarkers
Cardiometabolic and Renal Diseases
Patient Monitoring and Digital Biomarkers
Digital tools increasingly allow for remote monitoring of patients and generation of data which can be utilized for early identification of disease risk through novel biomarkers. These can help with timely diagnosis and improved treatment of cardio-metabolic conditions.
- We are looking for solutions which would allow a convenient and effortless way to monitor patients, track their disease progression and effectiveness of treatment as well as support early diagnosis of related conditions.
- We are also looking for companies developing novel biomarkers (digital, biological or in combination) and algorithms to predict the risk, progression or start of acute events in cardiovascular and renal diseases.
Open to both Growth and Advanced Tracks
Geographical Region Scalability: US, Germany, France, UK, China
Diagnosis and Treatment of CKD
Cardiometabolic and Renal Diseases
Diagnosis and Treatment of CKD
Chronic kidney disease (CKD) represents a major risk factor for cardiovascular disease. 37 million people in the US suffer from CKD, with core comorbidities including diabetes and hypertension. Due to symptomatology and underlying comorbidities, CKD can often go undiagnosed until it has progressed past its initial stages4.
- We are looking for solutions that facilitate the diagnostic process by identifying high risk patients and confirming the presence of CKD including the stage of progression.
- We are also looking for solutions that facilitate the treatment regimen or coordination of care (may be distinct) between HCPs and patients diagnosed with CKD.
Open to both Growth and Advanced Tracks
Geographical Region Scalability: US, Germany, France, UK, Spain, Italy
Mental Health and Mindfulness
Mental Health
Mental Health and Mindfulness
Mental health conditions cause 1 in 5 years lived with disability1. It is estimated that nearly one-third of people diagnosed with a serious, life-changing chronic illness (i.e. heart disease, cancer, diabetes) or disease will experience symptoms of depression and anxiety.2
- We are looking for digital health solutions and platforms which help people manage and improve their mental health and wellness.
- We are also looking for mental health solutions that actively engage with the patient’s inner circle such as caretaker, friends, family (spouse, children, etc.) involved in their care.
Open to both Growth and Advanced Tracks
Geographical Region Scalability: US, EU, China
References:
Cardiometabolic and Renal Diseases challenges Sources:
- https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
- https://pubmed.ncbi.nlm.nih.gov/28915435/
- https://www.tandfonline.com/doi/full/10.1080/1750984X.2016.1183222
- https://www.cdc.gov/kidneydisease/pdf/2019_National-Chronic-Kidney-Disease-Fact-Sheet.pdf
Mental Health challenges sources:
Why should you be interested in the Growth Track?

We provide you
with the financing
you need to take off
Our Growth Track startups gain a EUR 25,000 to EUR 100,000 convertible loan.
Our success stories
24+
Growth Track companies
$71.6M
Total funding raised
$122M
Total Alumni Value
Our success stories
24+
Growth Track companies
$71.6M
Total funding raised
$122M
Total Alumni Value

Mentorship by
industry experts
Growth Track Startups receive personalised mentorship, by Bayer executives and external industry experts. Individualised coaching ensures Startups enter the healthcare market successfully.
Can’t see anything that your solution is suitable for?
Check out our regular event series “Pitch Club” which provides a stage to extraordinary digital health startups